陕西医学杂志2011，Vol.40Issue(10)：1369-1371,3.
重组人血管内皮抑素联合化疗治疗晚期头颈部癌疗效观察
The clinical effects and safety of Rh-endostatin/Endostar combined chemotherapy for metastatic head and neck neoplasms
王峥 1董济民 1李民 1张晓炜 1丁海霞 1李蓉2
作者信息
- 1. 西安市中心医院,西安710003
- 2. 西安交通大学医学院第一附属医院
- 折叠
摘要
Abstract
Objective:To observe the clinical efficacy and safety of Rh-endostatin /Endostar,a new molecular targeted antitumor agent, combined with chemotherapy on metastatic head and neck neoplasms. Methods: 22 cases of metastatic head and neck neoplasms confirmed by histopathology or cytopathology were administered of 12 ~ 15mg Rh-endostatin /Endostar from dayl to dayl4. The chemotherapy agents were: capecitabine 1500~2000mg/(m2·d) ,dl-dl4,or TS-1 120mg/d, dl-dl4,21 days was 1 cycle. The toxicity was evaluated after 1 cycle and the efficacy was evaluated after 2 cycles. Results :22cases completed 108 cycles with a median 4 cycles. There was no case achieved CR,2 cases achieved PR, 9 cases were SD and 6 cases were PD, overall response rate(RR = CR+PR) was 9. 09%,and disease control rate DCRCCR + PR+SD) was 72. 7%. The quality of life (QOL) were improved in 19 cases(86. 3%). The median TTP was 10 months and the median survival time was 16 months. The main toxicities related to endostar was mildly cardiac toxicity (ECG T wave and ST-T changes, mild hypertension) in 3cases, other toxicities were related to chemotherapy gents. Conclusion:There are better efficacy of endostar combined with the related chemotherapy on the metastatic head and neck neoplasms and QOL of such patients may be improved with low toxic and good safety,so it seems to be an effective salvage regime.关键词
头颈部肿瘤/药物疗法/内皮抑素类/治疗应用/抗肿瘤联合化疗方案Key words
Head and neck neoplasms/drug therapy/Endostatins/therapeutic use/Antineoplastic combined chemotherapy protocols分类
医药卫生引用本文复制引用
王峥,董济民,李民,张晓炜,丁海霞,李蓉..重组人血管内皮抑素联合化疗治疗晚期头颈部癌疗效观察[J].陕西医学杂志,2011,40(10):1369-1371,3.
